Abstract
Purpose
To evaluate the functional and morphological outcomes of postoperative systemic steroid therapy after successful macular surgery in eyes with macular edema due to idiopathic macular epiretinal membranes (ERMs).
Design
Prospective, randomized, investigator-masked, controlled clinical study.
Methods
Twenty-eight patients scheduled for 23-gauge vitrectomy combined with ERM and inner limiting membrane (ILM) peeling for macular edema due to ERM were included in this single center trial. Patients were randomized to receive oral steroid therapy (Prednisolone, 100 mg per day for 5 days) or no oral steroid (control group) after surgery. Main outcome measures included best corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study), central retinal thickness (CRT), retinal volume (RV), and macular morphology as determined by spectral domain optical coherence tomography (SD-OCT, Cirrus). Examinations were carried out preoperatively and at week 1, at months 1 and 3, postoperatively.
Results
At month 3, mean BCVA improved to a eight-letter gain in each study group (P<0.01 compared with baseline for both groups), showing no statistically significant difference between both the groups (P=0.19). Morphologically, retinal surface folds resolved within 1 month after surgery in both treatment groups, followed by a progressive recovery of retinal layer integrity and a statistical significant (P<0.01) decrease in CRT and RV without significant differences between both groups (P=0.62, P=0.13, respectively, ANOVA between the groups).
Conclusion
The early postoperative use of systemic steroid treatment after successful vitrectomy combined with ERM and ILM peeling does not seem to improve significantly the anatomic and functional outcomes in eyes with ERM.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Gandorfer A, Rohleder M, Kampik A . Epiretinal pathology of vitreomacular traction syndrome. Br J Ophthalmol 2002; 86: 902–909.
Massin P, Allouch C, Haouchine B, Yoshimura N . Optical coherence tomography of idiopathic macular epiretinal membranes before and after surgery. Am J Ophthalmol 2000; 130: 732–739.
Michalewski J, Michalewska Z, Cisiecki S, Nawrocki J . Morphologically functional correlations of macular pathology connected with epiretinal membrane formation in spectral optical coherence tomography (SOCT). Graefes Arch Clin Exp Ophthalmol 2007; 245: 1623–1631.
Pesin SR, Olk RJ, Grand MG, Boniuk I, Arribas NP, Thomas MA et al. Vitrectomy for premacular fibroplasia. Prognostic factors, long-term follow-up, and time course of visual improvement. Ophthalmology 1991; 98: 1109–1114.
Schwab F . Cortison und Auge. Wr Med Wochenschrift 1958; 108: 839–842.
Jonas JB, Söfker A . Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425–427.
Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA . Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust NZJ Ophthalmol 1998; 26: 277–281.
Weller M, Wiedemann P, Heimann K . Proliferative vitreoretinopathy—is it anything more than wound healing at a wrong place? Int Ophthalmol 1990; 14: 105–117.
Wiedemann P . Drug treatment of proliferative vitreoretinopathy. Fortschr Ophthalmol 1989; 86: 115–120.
Stanbury RM, Graham EM . Systemic corticosteroid therapy—side effects and their management. Br J Ophthalmol 1998; 82: 704–708.
Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 12: 667–673.
Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA . Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593–598.
Fine HF, Iranmanesh R, Iturralde D, Spaide RF . Outcomes of 77 consecutive cases of 23-gauge transconjunctival vitrectomy surgery for posterior segment disease. Ophthalmology 2007; 114: 1197–1200.
Gupta OP, Ho AC, Kaiser PK, Regillo CD, Chen S, Dyer DS et al. Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol 2008; 146: 193–197.
Tewari A, Shah GK, Fang A . Visual outcomes with 23-gauge transconjunctival sutureless vitrectomy. Retina 2008; 28: 258–262.
Gordon DM, McLean JM . Effects of pituitary adrenocorticotropin hormone (ACTH) therapy in ophthalmic conditions. JAMA 1950; 142: 1271–1276.
Olson JA, Steffensen EN, Margulis RR, Smith RW, Whitney EL . Effect of ACTH on certain inflammatory diseases of the eye: a preliminary report. JAMA 1950; 142: 1276–1278.
Woods AC . Clinical and experimental observations on the use of ACTH and cortisone in ocular inflammatory disease. Am J Ophthalmol 1950; 33: 1325–1349.
Ruhmann AG, Berliner DL . Influence of steroids on fibroblasts. II. The fibroblast as an assay system for topical antiinflammatory potency of corticosteroids. J Invest Dermatol 1967; 49: 123–130.
Jonas JB, Hayler JK, Söfker A, Panda-Jonas S . Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468–471.
Bynoe LA, Weiss JN . Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 2003; 135: 382–384.
Koerner F, Merz A, Gloor B, Wagner E . Postoperative retinal fibrosis—a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol 1982; 219: 268–271.
Valone Jr J, Moser D . Management of rhegmatogenous retinal detachment with macula detached. Steroids, choroidal detachment, and acuity. Ophthalmology 1986; 93: 1413–1417.
Konstantinidis L, Berguiga M, Beknazar E, Wolfensberger TJ . Anatomic and functional outcome after 23-gauge vitrectomy, peeling, and intravitreal triamcinolone for idiopathic macular epiretinal membrane. Retina 2009; 29: 1119–1127.
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336–340.
Zkiris A, Erkilic K . Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005; 40: 63–68.
Tsujikawa A, Fujihara M, Iwawaki T, Yamamoto K, Kurimoto Y . Triamcinolone acetonide with vitrectomy for treatment of macular edema associated with branch retinal vein occlusion. Retina 2005; 25: 861–867.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ritter, M., Sacu, S., Matt, G. et al. Use of systemic steroid after successful macular surgery in eyes with epiretinal membrane: a randomized, controlled clinical study. Eye 25, 1284–1293 (2011). https://doi.org/10.1038/eye.2011.190
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.190
